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Paul H. Davisa
Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USAa; College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USAb;
Division of Infectious Diseases, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USAc
Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment
options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally,
no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. There-
fore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds
that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data
are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and poten-
tially to extend our knowledge of the parasite.
Toxoplasma gondii, a common protozoan parasite, has the abil-ity to infect nearly all warm-blooded animals, including hu-
mans, on all seven continents (1–3). This infection, while often
asymptomatic in otherwise-healthy individuals, can cause severe
disease or death in immunocompromised individuals, as well as
severe congenital defects in prenatally infected infants. T. gondii is
often acquired through the consumption of contaminated foods,
either from undercooked meats or inadequately washed fruits and
vegetables. Exposure to contaminated water is also a significant
risk factor for infection, as contaminated water sources have been
implicated in multiple outbreaks (4–6). Chemotherapy for treat-
ing toxoplasmosis is currently limited to the acute parasitic life
stage (tachyzoite) of the infection and frequently consists of com-
bination treatments, most often the antifolates pyrimethamine
and sulfadiazine (7). Despite the ability to coadminister folinic
acid orally with pyrimethamine, patients can suffer hematopoietic
deficiencies, among other adverse effects, due to folate synthesis
inhibition (8). Moreover, sulfadiazine has one of the highest rates
of allergic reactions to an antibiotic reported in the United States,
affecting 3 to 6% of the population (9, 10).
For women who become infected while pregnant, the treat-
ment protocol is less well-defined; indeed, no regimen of treat-
ment for expecting mothers is FDA approved (11). Often, congen-
itally infected infants are placed on an aggressive regimen of
pyrimethamine and sulfadiazine for a period of 6 to 12 months
immediately after birth, although the child remains at a high risk
of later manifestations of neurological deficits regardless of the
clinical symptoms presented at birth (12).
METHODS
In order to address these deficits, thousands of experimental com-
pounds have been synthesized and investigated for activity against
T. gondii. This work details the outcome of a comprehensive re-
view of the literature, including articles accessed from PubMed
with the following parameters: a publication date between 1 Jan-
uary 1980 and 28 June 2016; English as the primary language of the
publication; containing the keywords “toxoplasm* AND (drug*
or treatment*)”. A total of 5,504 items were filtered to identify
primary literature sources that evaluated the in vitro or in vivo
efficacy of compounds that were not derivatives of clinically avail-
able drugs used to treat toxoplasmosis (13); thus for the purpose
of this review, they were considered “experimental compounds”
due to their novelty and lack of clinical availability. Compounds
with 50% inhibitory concentrations (IC50s) of10 M were not
considered unless the compound had demonstrated efficacy in
vivo. Additionally, compounds were excluded if the IC50 was de-
termined based solely on the less-reliable enzyme-linked immu-
nosorbent assay method (14). Clinically available drugs (13) and
natural products (15) with activity against T. gondii are not con-
sidered in this review.
The experimental compounds in this review are generally di-
vided by the methodology by which they were discovered, then by
the predicted mode of action (MoA). The compounds identified
as part of mid- or high-throughput screens are listed in Table 3,
regardless of their MoA status. Those that have a known or sus-
pected MoA are listed in Table 1, while those without a known or
suspected MoA are listed in Table 2. All compounds described in
the tables have been indexed numerically according to their order
of appearance, with compound structures available in Tables S1 to
S3 in the supplemental material.
For promising anti-Toxoplasma compounds, assessment of
their ability to control T. gondii growth is a key step in drug devel-
opment. Traditionally, successful compounds demonstrate the
following: an IC50 under 10 M, except in cases where the com-
pound is used in combination with another compound; a high
therapeutic index; and an ability to increase survival of an infected
host animal after infection with a lethal dose of T. gondii (13).
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Promising compounds also ideally demonstrate marked decreases
in brain and muscle parasite cyst (bradyzoite) counts, a measure
of chronic infection; however, this has not been established to be
clinically significant. As more is learned about the potentially del-
eterious effects of chronic infections, this may become a greater
consideration (16). While few reviewed compounds have absorp-
tion, distribution, metabolism, and excretion (ADME) data, a lead
compound should demonstrate favorable pharmacokinetic char-
acteristics to avoid a late-stage failure during development (17).
COMPOUNDS WITH PROPOSED MODES OF ACTION
Interference with invasion or egress. Host cell invasion and
egress ofT. gondii are two distinct, complex, vital processes for the
survival of the parasite. During acute infection, T. gondii
tachyzoites require invasion of a host cell, formation of a parasi-
tophorous vacuole, replication, and egress. Invasion is thought to
be conducted through the formation of a junction between the
apical end of the parasite and the host cell plasma membrane (18).
The parasite uses an actin-myosin motor system to enter the host
cell while surrounding itself in the newly formed vacuole or mem-
brane arising from the host plasma membrane. Examples of com-
pounds that specifically target invasion are pyridinylpyrroles (19)
and benzophenones (20), which target cyclic GMP-dependent ki-
nase, a parasite protein implicated in the gliding motility and mi-
croneme adhesion ofT. gondii and other coccidians to the host cell
plasma membrane (21) (Table 1). The most potent of these, pyr-
idinylpyrrole (compound 4), had an in vitro IC50 of 0.32 M, and
increased the survival rate of mice infected with a lethal dose of
parasites by 90% when the drug was administered twice a day at 50
mg/kg of body weight (19, 21, 22).
T. gondii remains in the parasitophorous vacuole for the dura-
tion of its asexual reproduction and must egress in order to main-
tain virulence. Egress, a less-well-understood process, requires the
parasite to pass through both the established parasitophorous
vacuole and the host plasma membrane (18). While this cycle
has been demonstrated to be potassium and calcium dependent
and may involve host coordination, specific mechanisms are not
known (23). An important parasite protein for both invasion and
egress, calcium-dependent protein kinase 1 (TgCDPK1), has been
shown to be targeted by pyrazolopyrimidines (24) and benzoyl-
benzimidazoles (25) (Table 1). This parasite target is part of an
important signaling pathway involved in gliding, a required mo-
tion for T. gondii to cross the host cell’s plasma membrane (26).
Other compounds that affect both invasion and egress are dini-
troanilines (27) and diaryl ureas (28), which are suspected to de-
stabilize microtubules and myosin tail interactions, respectively.
Inhibition of DNA synthesis. The ability to replicate genetic
information is a central aspect of reproduction for all organisms.
During this process, T. gondii has a number of salvage pathways
and host-scavenging properties to support its nucleotide needs.
This is one process in which T. gondii differs significantly from its
apicomplexan relative, Plasmodium falciparum. While P. falcipa-
rum performs almost exclusively de novo pyrimidine synthesis, T.
gondii balances salvage with de novo synthesis of pyrimidine nu-
cleotides (29). Additionally, purine de novo synthesis is not per-
formed in T. gondii; rather, the precursors are imported from the
host through specialized nucleobase transporters (29).
Because of the diversity found in eukaryotic DNA synthesis,
many clinically available antiparasitics are capable of targeting this
process. Pyrimethamine and sulfadiazine, two of the most impor-
tant clinically used drugs in the treatment of toxoplasmosis, fall
within this category. These drugs target dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS), respectively;
both are enzymes active in the folate pathway (30). Without folate,
the synthesis of new thymidine nucleotides is halted, eventually
interrupting the cell cycle of the parasites. Unfortunately, specific
inhibition of parasite DHFR is not possible with pyrimethamine,
due to its homology with human DHFR; thus, host toxicity is high.
Other inhibitors of DHFR have been extensively studied and doc-
umented elsewhere in the literature (31–34) and include 2,4-di-
aminopyrido 2,3-dipyrimidines (35), experimental sulfonamides
(36), 2,4-diaminopteridines, and triazines. Based on available in
vitro data, the most promising of the experimental DHFR inhibi-
tors are the triazines; one of these, compound 14, has an IC50 of
0.02 M (37).
Sulfadiazine demonstrates greater parasite specificity because
of the suspected noneukaryotic origin of the DHPS enzyme; it is
not found in humans or most other higher eukaryotes (38). A
variety of novel sulfonamides, which target DHPS, have also dem-
onstrated efficacy against T. gondii, such as compound 16, with an
IC50 of 0.05 M (36, 39) (Table 1). Other inhibitors of the DNA
synthesis pathway in T. gondii generally target enzymes involved
in the synthesis of individual nucleotides. Inosine-5=-monophos-
phate dehydrogenase, an important component of guanine syn-
thesis, is inhibited by phthalazinones (40) through interaction at
the NAD binding site (41). Additionally, parasite adenosine ki-
nase, used in purine incorporation, binds 6-benzylthioinosine an-
alogues as subversive substrates (42).
Most eukaryotes utilize methylation as a form of epigenetic regu-
lation of transcription; however, in Toxoplasma tachyzoites, this
has not been shown to be a source of control (43). Instead,
S-adenosylmethionine (SAM)-dependent methyltransferases,
which are not found in humans, are critically important in
multiple parasitic metabolic pathways due to their other meth-
ylation functions (e.g., protein tagging). One compound, 1-[4-
(4-nitrophenoxy)phenyl]propane-1-one (compound 21) (Table
1), is thought to affect class I SAM-dependent methyltransferases,
though vacuolar ATP synthase subunit C is another potential tar-
get (44).
Inhibition of steroid synthesis. T. gondii is capable of synthe-
sizing some steroids that it requires, and it is dependent on the
host for others (45, 46). It has been shown that the mevalonate
pathway, present and functional in most eukaryotes, including
humans, does not function in T. gondii, likely forcing the parasite
to scavenge from the host or use alternative pathways to acquire
needed steroids (47). One alternative pathway is the 1-deoxy-D-
xylulose-5-phosphate (DOXP) pathway, which produces isopen-
tenyl diphosphate and dimethylallyl diphosphate, both precursors
to isoprenoids and essential molecules for parasite membrane
support and cellular signaling (48, 49). The aryloxyphenoxy de-
rivatives (Table 1) inhibit the synthesis of these precursors, pre-
venting the formation of isoprenoids in the parasite, thereby dis-
rupting multiple metabolic pathways and membrane structures
within T. gondii. In more recent work (50), acyl coenzyme A
(CoA):cholesterol transferase (ACAT) inhibitors were found to
prevent cholesterol esterification by the parasite, an integral step
of cholesterol uptake from the host (51) (Table 1).
Additional proposed inhibitors of T. gondii’s sterol synthesis
have focused on therapies that target the parasite’s bifunctional
protein, farnesyl diphosphate/geranylgeranyl diphosphate syn-
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thase (TgFPPS) (47). Multiple classes of TgFPPS inhibitors have
been identified, including bisphosphonates and quinuclidines
(Table 1). Of these, a quinuclidine, compound 27, has the lowest
IC50, at 0.19 M; however, it has not been tested in vivo (52, 53).
Many bisphosphonates are able to act on T. gondii specifically;
however, the host’s farnesyl diphosphate synthase and gera-
nylgeranyl diphosphate synthase are inhibited by one subclass of
bisphosphonates which also inhibits TgFPPS (47). Because of this,
it has been suggested that the use of statin drugs in combination
with antiparasitic treatment may be beneficial. Azasteroids do not
have a defined mechanism of action in T. gondii, although based
on data from other parasites, it is believed to be either due to the
unregulated uptake of sterols, which causes damage to organelles and
membranes, or due to the potential effects on the methylation status
of genes related to phospholipid biosynthesis (54). One such com-
pound, azasteroid, compound 26, has a promising IC50 of 0.12 M,
but it is yet to be tested for in vivo activity (55) (Table 1).
Fatty acid synthesis inhibition. Fatty acid synthesis (FAS) in
apicomplexans is a process distinct from that of its analogue in
mammals because of the presence of the apicoplast, an organelle
acquired via secondary endosymbiosis (56). The fatty acids pro-
duced in the FASII pathway of the apicoplast are critical for or-
ganelle biogenesis and survival, despite the ability of T. gondii to
scavenge some fatty acids from the host cell (57, 58). Therefore,
FASII pathway enzymes are attractive drug targets. One such en-
zyme is-ketoacyl-acyl carrier protein KASI/II, which plays a role
in elongation of fatty acids in the FASII pathway and is specifically
inhibited by thiolactomycin analogues in prokaryotes, and likely
in T. gondii (57, 59, 60) (Table 1). Another FASII enzyme believed
to be a drug target in fatty acid synthesis is enoyl acyl-carrier pro-
tein reductase, an enzyme responsible for the second reduction
step in FASII (61). Inhibition of this enzyme’s NAD-complexed
form is easily achieved with triclosan, a common antibacterial
found in soaps and other personal hygiene products; however, the
NADH-complexed form is not targeted by this common antibi-
otic (62). Therefore, various benzimidazoles, which target the re-
duced form of the enzyme in bacterial organisms, have a potential
MoA inT. gondii; however, none of these benzimidazoles has been
shown to inhibit T. gondii enoyl reductase isolated protein. In-
stead, in vitro analyses of the parasite’s susceptibility to the com-
pounds have revealed that the compound has other unknown par-
asiticidal mechanisms. The target is still thought to involve FAS
due to structural similarity to a known compound, chlormidazole,
which has activity against a FAS methylase in organisms that, like
T. gondii, lack the FASII pathway (62).
Outside of the FASII pathway, the parasite synthesizes other
fatty acids not found in humans, including pantothenate. The
pantothenate pathway in T. gondii is thought to be conserved
from a common prokaryotic ancestor or to have been acquired
through horizontal gene transfer (63). Due to its similarity to
the prokaryotic enzyme, the parasite’s pantothenate synthetase
can be specifically targeted with acylsulfonamides, inhibitors
originally developed for Mycobacterium tuberculosis (63) (Table
1). Acylsulfonamide, compound 28, inhibits T. gondii growth in
vitro with an IC50 of 0.02 M, and it exhibits a high therapeutic
index compared to other fatty acid synthesis inhibitors, with a
median toxic dose (TD50) of1 mM on HFF host cells.
Inhibition of virulence factors or host interactions.Apicom-
plexan parasites manipulate the host cell’s signaling pathways,
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ponents in order to create an environment in which they can sur-
vive (64–68). Without this ability, the host cell’s innate defense
mechanisms could overcome the parasite and prevent its repro-
duction or egress (69). Pyridinylimidazole, compound 31, (70)
inhibits T. gondii in vitro with an IC50 of 0.8 to 5 M and inhibits
the activation of activin-like kinases 4, 5, and 7, which are specific
host cell signaling receptors for the activation of hypoxia-induc-
ible factor 1, a host cell transcription factor required for T. gondii
growth that is manipulated by the parasite in infected host cells
(71) (Table 1). In addition to potently inhibiting this pathway,
compound 31 also inhibits mitogen-activated protein (MAP) ki-
nase 1, a parasite enzyme involved in invasion (72).
Inhibition of transcription. Transcriptional regulation is im-
portant for proper functioning of parasitic metabolism and is par-
tially attained through chromatin packaging (73). Apicomplexan
parasites and mammals use histone acetylation as a major source
of regulation, and the histone deacetylation enzymes are nearly
homologous (74). For this reason, histone hyperacetylation or
deacetylation is not a parasite-specific process, which has been
demonstrated with compound 33 (75), a fungal metabolite that
simultaneously targets histone deacetylase in T. gondii and the
host, as assessed by enzyme binding assays (Table 1). Despite this
challenge, some investigators have identified compounds that af-
fect histone deacetylase (HDAC) processes, such as enzyme
HDAC3, in a more apicomplexan-specific manner (76). Com-
pounds 34 and 35 are two examples of this, which have T. gondii
IC50s of 7.6 nM and 39 nM, respectively. Host cell toxicity remains
a concern with compound 34; the TD50 for human host cells is less
than 10 times greater than the IC50 forT. gondii, but compound 35
seems to fare better on host cells with a TD50 of10 M in HS68
cells (74, 77) (Table 1). Garcinol, derived from the Garcinia indica
fruit, is another compound that affects histone acetylation, target-
ing a family of lysine acetyltransferases (KAT) enzymes required
for T. gondii tachyzoites to replicate successfully (78). Addition-
ally, other (nonhistone) substrates of these compounds may be
affected, contributing to the overall host cell toxicity and to the
efficacy of the compound against the parasite (79). Indeed,
HDACs have various roles in many biological processes, including
DNA repair and cell cycle regulation.
Inhibition of reproduction or differentiation. T. gondii has
two distinct asexual life stages in humans: the tachyzoite, the stage
associated with acute infection, and the bradyzoite, associated
with the latent infection (80). Replication of the parasite within
the parasitophorous vacuole or cyst is achieved through mitosis.
Lactacystin, compound 38, is a recently discovered proteasome
inhibitor capable of interfering with mitosis; parasites treated with
this compound do not perish, but rather halt cellular replication
until the compound has been metabolized or removed, even if the
treatment period lasts for several days (81). Because of this, no
IC50 could be generated for this class of inhibitor, although signif-
icant effects were noted at 2M. While the parasitostatic effects of
compound 38 present limitations to development, no host cell
toxicity was noted even at the highest compound concentration
studied (2 M).
When the parasite encounters stressful conditions, such as an
immune system response or metabolic insult, the rapidly dividing
tachyzoite undergoes differentiation to the slowly replicating bra-
dyzoite (82). This shift significantly changes the genetic expres-
sion profile of T. gondii and leads to a slower-growing, hardier
encysted form of the parasite that localizes to the brain and mus-
cular tissue of the host. Two lactate dehydrogenase (LDH) iso-
forms are differentially expressed during the tachyzoite and bra-
dyzoite stages. LDH1 is expressed mainly in the tachyzoite stage,
while LDH2 is expressed during the bradyzoite stage; both are
substantially different from the mammalian LDH (83). The cot-
ton plant-derived gossypol and its derivatives (exemplified by
compound 37) have been shown to be potent LDH2 inhibitors
(enzyme Ki, 1.1 M) and are somewhat active against LDH1 (en-
zyme Ki, 6.1M), with an IC50 of 5 to 10M against intracellular
tachyzoites (84). However, these compounds have not been tested
against the bradyzoite form.
Effects on reactive oxygen species regulation. Through the
combination of the CD8 T-cell response and interferon gamma-
mediated activation, a competent host immune system is capable
of subduing most of the tachyzoites produced in an acuteT. gondii
infection. One facet of this response is the production of reactive
oxygen species (ROS) by macrophages, a response induced by
cationic dyes (85), quinoline derivatives (86), and various alka-
loids (87) (Table 1). Alkaloid compounds 44 and 45 have the
lowest IC50 values in this category (0.7 nM), but host cell toxicity
is a concern: in THP-1 host cells, compound 44 demonstrated a
TD50 of 1 nM, while compound 45 had a more favorable TD50 of
0.392 M (86).
Quinones, though extensively studied, do not have an estab-
lished MoA in Toxoplasma. A parasite-specific NADH dehydro-
genase type II complex, essential to cellular respiration, binds
some quinones with high affinity, indicating that this may be one
target of this compound class (88). Without the ability to reduce
oxygen into water, the production of ROS would be promoted,
likely causing damage to parasite mitochondria (89).
COMPOUNDS WITHOUT KNOWN OR SUSPECTED MODES OF
ACTION
Compounds that lack a known or suspected MoA, but demon-
strate anti-Toxoplasma activity, present an opportunity for further
exploration. Of note, pyrimethamine, atovaquone, and sulfadia-
zine did not have a known MoA at the time that they were FDA
approved; thus, the lack of a MoA does not necessarily prevent an
otherwise-promising compound from progressing in develop-
ment.
Of the compounds that do not have specific mechanisms elu-
cidated, one stands out as particularly interesting: a semisynthetic
artemisinin, compound 54. Artemisinin, the precursor of all of the
semisynthetic artemisinin derivatives used to treat malaria, was
isolated from the plant Artemisia annua (90). Compound 54 has
poor aqueous solubility (91); however, due to its high lipophilic-
ity, compound 54 is suspected to have high blood-brain barrier
penetration; indeed, further studies on reactivation of latent T.
gondii infections have shown that this compound has some ability
to protect mice from immunosuppression-induced reactivated
infections (90). Because of the potency of this compound, as well
as closely related derivatives (artemisone) passing FDA phase I
trials (92), compound 54 and other artemisinin derivatives are
promising candidates for further study.
Other compound groups with no known MoA include metals
and metal complexes; images taken from one silver exposure
study demonstrated significant morphological alterations, indi-
cating that the MoA likely involves some form of mechanical dam-
age to the cellular surface of the parasite (Table 2). Of these com-
pounds, the highly effective metal ion complex, compound 50
Minireview
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(IC50, 0.0187 M) appears to be the most the most promising
(93).
COMPOUNDS IDENTIFIED IN SCREENS
Most clinically available anti-Toxoplasma drugs were originally
developed to treat infections caused by other protozoal or bacte-
rial pathogens (94). Traditionally, compounds active against Plas-
modium were often subsequently tested against T. gondii. More
recently,T. gondii-specific high-throughput screens (HTS) are be-
coming more common for discovery of compounds active against
this protozoan. However, the downside of screening is that little
information other than the compound structure and IC50 data are
readily gathered, leaving significant work to detail additional fea-
tures. For the purpose of this review, T. gondii chemical screens
were classified into 4 different groups: (i) cell-based phenotypic
screens; (ii) target-based in vitro biochemical screens; (iii) chem-
informatics-based virtual screens; (iv) drug-repurposing screens.
The inherent value of such screens, as seen in Table 3, is to provide
starting points for subsequent characterization and optimization.
Cell-based phenotypic screens. In cell-based phenotypic
screens, compounds are evaluated against live parasites by mea-
suring the in vitro parasite replication rate by using strains that
express -galactosidase or fluorescent proteins, or by employing
the [3H]uracil incorporation assay (95–97). As an example of the
power of this approach, Table 3 presents a list of the promising
compounds discovered using cell-based screens. For example, a
small focused screen (98) identified 8 compounds with a biphe-
nylimidazoazine scaffold with IC50s of0.6 M against T. gondii
(Table 3); these compounds also demonstrated broad antipara-
sitic effects against several apicomplexan parasites, including
P. falciparum, Neospora caninum, Eimeria tenella, and Besnoitia
besnoiti, suggesting that they were rather nonspecific inhibitors of
T. gondii. In a recent high-throughput screnning (HTS) approach
(99), 6,811 compounds were screened, and N-4-ethyl-benzoyl-2-
hydroxybenzamide, compound 80, was identified, with an IC90
value of0.031 M. Using an insertional mutagenesis approach,
the authors identified a putative target gene, adaptin-3, which is
part of a secretory protein complex responsible for the secretion of
micronemes, rhoptries, and dense granules. This compound was
optimized to yield compound 81, which has an IC90 value of
0.016 M. Compounds 80 and 81, at respective doses of 50 and
20 mg/kg/day, protected mice against T. gondii acute infection.
However, these compounds had low specificity for T. gondii, as
they were also active against other protozoan parasites, including
Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania
donovani, and P. falciparum (100). Another phenotypic study
identified endochin-like quinolone compounds 68 and 69 with in
vitro IC50s of 0.1 and 0.007 nM, respectively (101) (Table 3). These
compounds are orally bioavailable and, at doses of 0.3 to 1.0 mg/
kg/day given once a day for 5 days, prevented acute toxoplasmosis
in a murine experimental model. Moreover, these compounds
drastically reduced the cyst burden in a latent murine infection
model. Their low IC50 combined with the ability to inhibit acute
and chronic forms of infection makes these compounds promis-
ing anti-Toxoplasma therapeutic leads.
In addition to measuring in vitro growth rate, some T. gondii
phenotypic screens identified compounds that inhibited host cell
attachment and invasion. Using this approach, a focused small-
molecule screen identified cysteine protease inhibitors that block
invasion (102). Other screens have used dual-fluorescent image-
based high-content screening (HCS) to directly observe parasite
attachment and entry into the host cells (103, 104). Even though
phenotypic screens are capable of identifying new chemical enti-
ties, one drawback of the phenotype-based approach is the diffi-
culty in identifying target proteins. To circumvent this problem,
Hall et al. used a combination of HCS and chemical genetics to
screen a library of 1,222 inhibitors that covalently modified the
target protein and then applied click chemistry along with tandem
orthogonal proteolysis activity-based protein profiling to identify
target proteins. With this approach, they identified compound 67,
which blocks host cell invasion by inhibiting the activity of
TgDJ-1, a unique regulator of microneme secretion and motility
(104). These studies suggest that phenotypic screens combined
with chemical genetics or forward genetic screens (69), such as
drug-resistant strain generation via insertional mutagenesis or
chemical mutagenesis, are powerful approaches to identify new
drugs and drug targets.
Target-based in vitro biochemical screens. Target-based in
vitro biochemical screens usually involve a biochemical assay with
a purified recombinant protein. One of the major advantages of a
target-based screen is the possibility of screening or designing
drugs based on the enzymatic property or the crystal structure of a
protein. These screens were carried out on T. gondii even before
the availability of its genome sequence (105). Most of these screens
were focused on developing inhibitors against known essential
enzymes, such as DHFR, DHPS, and nucleoside triphosphate hy-
drolase (NTPase). However, due to the toxicity of clinically avail-
able antifolate drugs, many of the initial screens were focused on
identifying additional compounds that specifically inhibited T.
gondii DHFR (33, 34, 106–111) and DHPS (39, 112) while avoid-
ing host effects. Most of these small-scale screens were performed
to identify compounds that were active against these enzymes, but
very few of these studies reportT. gondii in vivodata (37, 113, 114).
One of the early target-based HTS in T. gondii was performed by
Asai et al., who screened 150,000 compounds against Tg-NTPases,
which are essential proteins for T. gondii tachyzoite replication
inside the parasitophorous vacuole (115) (Table 3). In this screen,
compounds 89, 90, and 91 were identified that inhibited T. gondii
growth in vitrowith IC50s of7.0M and inhibited NTPase I and
II enzymes with IC50s ranging from 1.3 M to 14.5 M.
Several target-based drug screens were also performed against
T. gondii CDPKs because, as described above, these kinases regu-
late essential biological processes, such as cell division, develop-
ment, motility, microneme secretion, invasion, and egress (116).
In addition, the ATP binding pockets of most of the apicomplexan
CDPKs have a gatekeeper residue with a smaller side chain,
whereas most of the ATP binding pockets in mammalian serine-
threonine protein kinases have a gatekeeper amino acid with a
bulky side chain. This property has been exploited to develop in-
hibitors specific for TgCDPK1, an essential kinase that regulates
gliding motility, invasion, and egress in T. gondii (117). Based on
structure-activity relationship (SAR) studies, a number of pyra-
zolopyrimidines were identified which specifically inhibit
TgCDPK1 and preventT. gondii growth at concentrations below 1
M (24, 118, 119). One of these, compound 86, is orally bioavail-
able and can reach tachyzoites in the brains of infected mice by
crossing the blood-brain barrier and reach therapeutic concentra-
tions (120). Interestingly, compound 86 has broad-spectrum an-
tiparasitic activity against several pathogens, such as Cryptospo-
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ridium parvum (121), Neospora caninum (122), and Plasmodium
falciparum (123).
Cheminformatics-based virtual screens. Cheminformatics-
based virtual screens are being performed to identify novel anti-
Toxoplasma compounds (87, 124, 125). The availability of crystal
structures for some of theT. gondii proteins and the improvement
in computational molecular modeling approaches facilitate this
approach. For example, a chemoinformatic virtual screen against
rhoptry protein 18 (ROP18) led to the identification of compound
93, which inhibits T. gondii growth in vitro with an IC50 of2 nM
(Table 3). In this screen, the authors performed in silico chemical
searches on 45,384 commercially available compounds and iden-
tified 17 of these, based on their expected activity and ADME
characteristics. From these 17 compounds, those authors identi-
fied compound 86 to be most potent against T. gondii in vitro.
Even though compound 93 was identified as a ROP18 inhibitor,
this compound has additional unidentified effects on the parasite.
Drug-repurposing screens. Drug-repurposing screens are
common in T. gondii drug discovery because drugs active against
one apicomplexan parasite are often active against other apicom-
plexans, due to the conservation of biochemical pathways between
these parasites. As a result, compounds active against Plasmodium
falciparum are often screened against T. gondii. Many compounds
now in clinical use are a result of these investigations (13). Screen-
ing of the open-access Medicines for Malaria Venture (MMV)
Malaria Box led to the identification of 7 anti-Toxoplasma com-
pounds with novel chemical scaffolds (126) (Table 3), the most
potent of which was compound 94, with an IC50 of 0.19M (126).
In another screen, approximately 15 broad-spectrum anti-Toxo-
plasma compounds, with IC50s below 10 M, were identified by
screening a library of 309,474 unique compounds against P. fal-
ciparum and testing a set of representative compounds against T.
gondii, Leishmania major, and Trypanosoma brucei.
CONCLUSION
Within this review, more than 50 chemotypes have been de-
scribed. Based on the identified characteristics, a number of spe-
cific compounds stand out as particularly notable. Pyridinylpyr-
role, compound 3, demonstrated 90% increased survival and low
organ parasite loads during an in vivo trial, with no sign of recru-
descence 12 months after the completion of treatment (19, 21)
(Table 1). Another promising compound class which inhibits fatty
acid synthesis are the acylsulfonamides, the molecular target for
which is not present in the host cell (63) (Table 1). Compound 28,
an acylsulfonamide, does not have any reported in vivo data, but it
has very low host cell toxicity in HFF cells (TD50,1 mM) com-
pared to its T. gondii IC50 (0.02 M), indicating it may have a
relatively high therapeutic index. One of the most promising com-
pounds identified via a screening assay was compound 86, a semi-
synthetic artemisinin (120). This compound is orally bioavailable
and capable of crossing the blood-brain barrier, with a survival
increase of 60% in treated mice (90). The endochin-like quino-
lones (compounds 68 and 69), also identified via screening, addi-
tionally demonstrate promising characteristics, such as a high
therapeutic index and efficacy against the acute and chronic stages
in vitro (Table 3).
Inhibition of translation is common against prokaryotic tar-
gets, but due to homology to host ribosomal components, it is
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targets mechanisms of translational control may offer additional
avenues for therapy (128).
In summary, with the expanding number of immunocompro-
mised individuals at high risk, the demand for new toxoplasmosis
treatment options is rising. Some of the novel compounds re-
viewed here may represent good starting points for the discovery
of effective new drugs against T. gondii. Increasing the medicinal
arsenal of anti-Toxoplasma therapeutics may yield a potent and
less toxic option for future patients.
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